These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19922501)

  • 1. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer.
    Kawai K; Akaza H
    Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.
    Lawrence NJ; Chan H; Toner G; Stockler MR; Martin A; Yip S; Wong N; Yeung A; Mazhar D; Pashankar F; Frazier L; McDermott R; Walker R; Tan H; Davis ID; Grimison P;
    BMC Cancer; 2018 Aug; 18(1):854. PubMed ID: 30157803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
    Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
    Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of good risk germ-cell tumours.
    Troost MM; Sternberg CN; de Wit R
    BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
    Fosså SD; Paluchowska B; Horwich A; Kaiser G; de Mulder PH; Koriakine O; van Oosterom AT; de Prijck L; Collette L; de Wit R;
    Br J Cancer; 2005 Nov; 93(11):1209-14. PubMed ID: 16251877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
    Daugaard G; Skoneczna I; Aass N; De Wit R; De Santis M; Dumez H; Marreaud S; Collette L; Lluch JRG; Bokemeyer C; Schmoll HJ
    Ann Oncol; 2011 May; 22(5):1054-1061. PubMed ID: 21059637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
    Culine S; Kerbrat P; Kramar A; Théodore C; Chevreau C; Geoffrois L; Bui NB; Pény J; Caty A; Delva R; Biron P; Fizazi K; Bouzy J; Droz JP;
    Ann Oncol; 2007 May; 18(5):917-24. PubMed ID: 17351252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial.
    Mead GM; Cullen MH; Huddart R; Harper P; Rustin GJ; Cook PA; Stenning SP; Mason M;
    Br J Cancer; 2005 Jul; 93(2):178-84. PubMed ID: 15999102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy for metastatic germ cell tumours of the testis].
    Culine S
    Rev Prat; 2007 Feb; 57(4):385-8. PubMed ID: 17455740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current medical management of patients with poor-risk metastatic germ-cell tumors.
    Albany C
    Curr Opin Urol; 2018 Sep; 28(5):474-478. PubMed ID: 29979236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [International study on testicular cancer: EORTC 30983: randomized phase II/III study of Taxol-BEP versus BEP in patients with Intermediate Prognosis Germ Cell Cancer].
    Rexer FH
    Urologe A; 2005 Sep; 44(9):1064-5. PubMed ID: 16265725
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors.
    Attili VS; Chandra RC; Anupama G; Loknath D; Bapsy PP; Dadhich HK; Babu GK
    J Cancer Res Ther; 2007; 3(3):150-2. PubMed ID: 18079577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
    Fizazi K; Le Teuff G; Fléchon A; Pagliaro L; Mardiak J; Geoffrois L; Laguerre B; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Cancel M; Juzyna B; Reckova M; Naoun N; Logothetis C; Culine S
    J Clin Oncol; 2024 Oct; 42(28):3270-3276. PubMed ID: 39167741
    [No Abstract]   [Full Text] [Related]  

  • 19. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
    Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
    J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
    de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
    Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.